Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogenic adipose-derived mesenchymal stem cells + autologous bone marrow mononuclear cells
- Development stage
- Unknown
- Lead developer
- Sophia Al-Adwan
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This experimental cell therapy combination is being evaluated for the treatment of newly diagnosed Type 1 Diabetes Mellitus (T1DM). It involves the administration of allogenic adipose-derived mesenchymal stem cells (AD-MSCs) in conjunction with autologous bone marrow mononuclear cells (BMMCs). AD-MSCs are utilized for their potent immunomodulatory and anti-inflammatory properties, which aim to halt the autoimmune destruction of insulin-producing beta cells. BMMCs, which contain a heterogeneous population of progenitor cells, are included to potentially support revascularization and the regeneration of the pancreatic microenvironment. The primary goal of this Phase I study, led by Sophia Al-Adwan, is to assess the safety and feasibility of this combined cellular approach in adult patients.
- Other names
- Adipose mesenchymal cells with bone marrow mononuclear cellsAD-MSC + BMMC
Beyond the preview
Go deeper on allogenic adipose-derived mesenchymal stem cells + autologous bone marrow mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogenic adipose-derived mesenchymal stem cells + autologous bone marrow mononuclear cells.